循环miRNA-141对前列腺癌的诊断和预后价值研究

 目的:研究血清miR-141在前列腺癌中的表达及临床意义。方法:采用实时荧光定量PCR检测75例前列腺癌和52例良性前列腺增生（BPH）患者，以及40例健康对照血清miR-141的相对表达水平。结果:前列腺癌血清miR-141的表达量较BPH和健康对照增高，差异有统计学意义（P＜0.01）。但miR-141在BPH组和对照组中的表达差异无统计学意义（P>0.05）。ROC曲线显示miR-141能够较好地区分前列腺癌与BPH（或健康对照），曲线下面积分别为0.785（95%CI∶0.689～0.823）和0.801（95%CI∶0.723～0.868）。血清miR-141表达与Gleason积分、临床分期和骨转移相关（均P<0.05），随着临床分期的增加，miR-141的表达水平增加；但miR-141表达量与患者年龄、肿瘤复发和血清前列腺特异性抗原水平无关(均P>0.05)。结论: 循环miR-141可作为非侵入性诊断前列腺癌并且判断其预后的分子标志物。

Circulating miRNA-141 as a non-invasive biomarker for prostate cancer detection and prognosis

AIM:To analyze circulating miR-141 in the serum as a non-invasive biomarker in the patients with prostate cancer (PCa) and benign prostate hyperplasia (BPH), and healthy individuals. METHODS:A total of 75 patients with PCa, 52 with BPH and 40 healthy individuals were enrolled into this study. Total RNA was isolated from the serum samples and the circulating levels of miR-141 were determined using quantitative real-time polymerase chain reaction. RESULTS:The serum levels of miR-141 were significantly higher in the patients with PCa compared to the patients with BPH and the healthy controls (P<0.01). The level of miR-141 in PCa group obviously differed from that in BPH group and healthy control group with high diagnosis performance, with areas under the curve of 0.785 and 0.801, respectively. No statistically significant difference of the serum miR-141 levels between the patients with BPH and healthy individuals was observed (P>0.05). The serum miR-141 level was also found to be related to Gleason score, clinical stage and bone metastasis status of the patients with PCa (P<0.05), and the patients with higher Gleason scores had higher serum miR-141 levels. No relationship was detected between miRNA-141 level and the patient’s age, biochemistry recurrence and serum prostate-specific antigen level (P>0.05 for all comparisons). CONCLUSION: Circulating miR-141 could serve as a non-invasive biomarker for prostate cancer diagnosis, staging and prognosis prediction.